The aim of this study was to evaluate the drug-drug interaction between pimodivir, a novel, non-nucleoside polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A virus polymerase complex, and oseltamivir, to assess the feasibility of this combination therapy. Furthermore, single-and multiple-dose pharmacokinetics and safety of pimodivir in healthy volunteers were assessed.
Introduction
Seasonal epidemics and the emergence and transmission of novel pandemic strains of influenza are associated with high risk of morbidity and mortality and pose an immense public health concern [1, 2] . Globally, an influenza epidemic is estimated to cause approximately 3-5 million cases of severe illness [3] and up to 600 000 respiratory deaths (up to 8.8 per 100 000 individuals) per year [4] . The 2009 H1N1 influenza pandemic in the United States resulted in an estimated 61 million cases, 274 000 hospitalizations and 12 500 deaths [5] .
The currently available antiviral agents for the treatment of influenza include neuraminidase inhibitors (NAIs) and the viral M2-protein inhibitors [6] . A major limitation of NAIs is that they need to be administered within 48 h of infection in uncomplicated patients to reduce the disease duration and severity of symptoms [7] . Also, the emergence of resistance to these antivirals has raised concerns, especially in patients who are immunocompromised or critically ill [8] [9] [10] . The M2 inhibitors are no longer used for this reason. These concerns with current medications emphasize the critical need for new treatment options with novel mechanisms of action. It has been speculated that combining influenza antiviral drugs with different modes of action might increase clinical effectiveness and reduce the risk of resistance development in these patients [6] .
Pimodivir (JNJ-63623872; formerly VX-787) is a novel, non-nucleotide inhibitor of the polymerase basic protein 2 (PB2) subunit of the influenza A that is active against H1N1, H7N9 and H5N1, as well as influenza A strains with reduced susceptibility to NAIs [11] . Pimodivir has also shown rapid onset of action, which could plausibly allow expansion of the treatment window for influenza [12] . Co-administration of pimodivir and oseltamivir has been evaluated in a preclinical study and has shown beneficial effects in lowering influenza viral loads [11, 13, 14] . In vitro, pimodivir is metabolized by cytochrome P450 (CYP) 3A and aldehyde oxidase followed by glucuronidation; pimodivir is a substrate of P-glycoprotein and a substrate and inhibitor of the organic anion transporting polypeptide (OATP) 1B1 [11, 12] . Oseltamivir is converted to oseltamivir carboxylate (active form) via carboxylesterases. Oseltamivir is a substrate of P-glycoprotein and peptide transporter (PepT) 1, whereas oseltamivir carboxylate is a substrate of multidrug resistance protein (MRP) 4 and organic anion transporter (OAT) 3 but not P-glycoprotein. Oseltamivir (parent and carboxylate) has no known effects on CYPs. Given the known pharmacologic profiles of the compounds, no drug-drug interactions were expected when combined. The present Phase 1 study was conducted to evaluate the pharmacokinetic interaction between pimodivir and oseltamivir and to assess the singleand multiple-dose pharmacokinetics of pimodivir in healthy volunteers.
Methods

Participants
Men and women (aged 18-55 years) with body mass index (BMI) between 18 and 30 kg m À2 who were assessed to be healthy based on physical examination, medical history, vital signs, 12-lead ECG, and laboratory at screening were included. Participants were non-smoking or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to screening. Participants were excluded if they were positive for hepatitis A, B, or C infection, human immunodeficiency virus type 1 (HIV-1), HIV-2 infection, urine drug test or if they had a clinically significant drug allergy, history of clinically significant disease, a clinically significant skin disease and/or any clinically relevant laboratory abnormalities at screening. Participants who previously received pimodivir in a multiple-dose study or in more than three single-dose studies were excluded. Participants were not allowed to consume any food or drink/beverage containing alcohol or quinine (24 h prior to dosing), any energy drinks (48 h prior to dosing) or caffeinated drinks (on the day of blood sampling) or grapefruit or grapefruit juice, citrus fruits, or vegetables from the mustard green family or charbroiled meats (7 days prior to dosing). Use of any concomitant medications or over-the-counter medications (including herbal medications or dietary supplements), except for paracetamol or ibuprofen, or hormone replacement therapy (postmenopausal women) were prohibited from 14 days prior to dosing.
Study design
This was an open-label Phase 1 study conducted in healthy participants in two parts. Part 1 was a randomized, threeway, crossover study to evaluate the drug-drug interaction between pimodivir and oseltamivir, both at steady-state. This part encompassed a screening phase, a treatment phase and a follow-up phase. Participants in fed condition were randomized to one of six cross-over treatment sequences according to the Williams crossover design [15] . ). There was a minimum 5-day washout period between each treatment session to prevent carry-over effects ( Figure 1 ). For all treatment sessions, patients were admitted to the study site on the morning prior to Days 1 and 5 and were discharged after the morning assessments on Days 1 and 5. Part 2 was a double-blind, randomized, placebocontrolled study to investigate the safety, tolerability and pharmacokinetics of pimodivir 600 mg b.i.d. Participants randomly received pimodivir 600 mg or placebo (3:1) b.i.d. on Days 1-9, followed by a single-dose pimodivir 600 mg or placebo respectively in the morning on Day 10.
The order for conducting the two study parts was not fixed. The study was conducted at the Janssen Clinical Pharmacology Unit, Merksem, Belgium, and in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice standards and applicable regulatory requirements. All participants provided written informed consent before study initiation and the study protocol was reviewed by the Independent Ethics Committee of Antwerp University Hospital, Belgium. The study was registered at http:// clinicaltrials.gov (NCT02262715) and at EudraCT (2014-002528-28).
Study evaluations
Venous blood samples for pharmacokinetic assessments were collected predose on Days Plasma concentrations of pimodivir were determined by protein precipitation of 50 μl aliquots. A stable isotope labelled internal standard was used. Separation was done on an XBridge C18 column, and detection was carried out using liquid chromatography-tandem mass spectrometry (LC-MS/MS) on an API-4000 with multiple reaction monitoring (MRM) transitions 400.2-248.0 and 408.2-248.0. The calibration range was 2.00 ng ml À1 to 10 000 ng ml À1 ;
log-log linear regression was applied. Plasma concentration of oseltamivir and oseltamivir carboxylate were determined by protein precipitation of 50 μl aliquots. Stable isotope labelled internal standards were used. Separation was done on an Agilent Zorbax 300-SCX column, and detection was carried out using LC-MS/MS on an AB Sciex triple quad 5500 with MRM transitions 313.1-166.0 and 316.1-167.0 for oseltamivir and internal standard, respectively and 285.1-138.0 and 288.1-139.0 for oseltamivir carboxylate and internal standard, respectively. The calibration range was 1.00 ng ml À1 to 250 ng ml À1 for oseltamivir and 10.0 to 2500 ng ml À1 for oseltamivir carboxylate; linear 1/x 2 regression was applied.
The methods were validated according to procedures that reflect the US Food and Drug Administration (FDA) guidelines and the European Medicines Agency (EMA) guidance on bioanalytical method validation. All validation parameters were within criteria.
Pharmacokinetic parameters were obtained using non-compartmental analysis (WinNonlin 6.2.1, Certara, Princeton, NJ) using actual time and the plasma concentration data. In Part 1, the pharmacokinetic parameters of interest were predose concentration (C 0h ) assessed on Days 3, 4 and 5 (from Treatments A and C for pimodivir and Treatments B and C for oseltamivir and oseltamivir carboxylate); and minimum plasma concentration (C min ), maximum plasma concentration (C max ), time to C max (t max ), and area under the plasma concentration-time curve over 12 h (AUC 12h ) as calculated using the linear-linear trapezoidal rule. In Part 2, pharmacokinetic parameters of interest assessed for pimodivir on Day 1 were C max , t max , AUC 12h ; on Days 8 and 9 was C 0h ; and on Day 10 were C 0h , C min , C max and t max .
Safety and tolerability were assessed throughout the study based on treatment-emergent adverse event (TEAE) recording, physical examination, laboratory testing, vital signs and 12-lead ECG findings. All events were classified according to MedDRA (Medical Dictionary for Regulatory Activities; version 17.0) preferred terms, and severity was determined according to the World Health Organization (WHO) toxicity grading scale [16] .
Statistical analysis
A total of 18 participants were planned to be enrolled in Part 1 to allow for dropouts. Assuming a sample size of 16 participants who would complete the study and within-participant coefficient of variation (CV) of 35% for pimodivir and oseltamivir AUC, the point estimate of geometric mean exposure ratio of each analyte after combined administration vs. administration alone was expected to be contained within 81.5% and 122.6% of the 90% confidence interval (CI). In Part 2, the sample size was not determined by statistical considerations. The pharmacokinetic analysis set included participants who had no protocol deviations. The safety population included all participants who received at least one dose of any study drug.
Plasma concentrations at each sampling time point, pharmacokinetic and safety parameters were summarized descriptively. Mean (standard deviation) plasma concentration-time profile of pimodivir, oseltamivir and oseltamivir carboxylate were graphically presented. The least square (LS) means of the log-transformed pharmacokinetic parameters (C min , C max and AUC 12h ) were estimated with a linear mixed-effects model, controlling for treatment, sequence and period, if applicable, with fixed effects and subject as a random effect. LS means and corresponding 90% CI limits derived from the model were backtransformed to the original scale. The no effect boundary for part 1 was considered to be a 90% CI within 80.00% to 125.00%. Table 1 .
Results
Patient disposition and demographics
Pharmacokinetics of pimodivir
In Part 1, administration of pimodivir alone or in combination with oseltamivir resulted in comparable C min (LS means ratio: 99%; 90% CI: 87-112%) and AUC 12h (LS means ratio: 104%; 90% CI: 92-118%) on Day 5 ( Figure 2) ; however, the C max of pimodivir increased by 1.31-fold (90% CI: 92-185%) in the presence of oseltamivir compared with pimodivir alone (Table 2 ). The median t max of pimodivir after co-administration with oseltamivir was 1.5 h compared with 3.0 h after pimodivir was administered alone.
In Part 2, the AUC 12h of pimodivir on Day 10 compared with Day 1 was 1.78-fold higher (90% CI of LS means ratio: 151-210%) and C max was 1.19-fold higher (90% CI of LS means ratio: 92-154%) (Table 3) , indicating some accumulation of pimodivir over time. The mean C 0h were generally comparable on Days 8 (462 ng ml À1 ), 9 (447 ng ml À1 ) and 10 (429 ng ml À1 ), indicating that steady-state conditions had been achieved prior to Day 8. The median t max was 
Pharmacokinetics of oseltamivir and oseltamivir carboxylate
In Part 1, the mean C 0h for both oseltamivir and oseltamivir carboxylate was comparable on Days 3 (1.88 and 194 ng ml À1 , Figure 2 Mean ± standard deviation plasma concentration-time profile of pimodivir after administration of pimodivir 600 mg twice daily alone and in combination with oseltamivir 75 mg twice daily on Day 5 (Part 1) Table 3 Steady-state pharmacokinetic parameters of pimodivir on Day 1 and Day 10 following administration of pimodivir 600 mg twice daily on Days 1-9 followed by a single dose of 600 mg on Day 10) in healthy volunteers (Part 2) (Table 4) . For oseltamivir carboxylate, C min , C max and AUC 12h were generally comparable between treatment groups, based on the 90% CI of the ratios of the LS means (Table 4 ). Median t max on Day 5 for oseltamivir was approximately 1.3-1.5 h and for oseltamivir carboxylate was 4 h postdose for both treatments (Figure 4 ).
Safety
In All cases of diarrhoea were grade 1, except for one case which was grade 2 reported in a participant receiving pimodivir in Part 1. One participant on pimodivir 600 mg b. i.d. for 4 days discontinued treatment due to viral infection (mild in severity), which resolved after withdrawal. There were no clinically meaningful changes in clinical laboratory evaluations, vital signs, physical examinations or ECGs. In both the parts, there were no deaths, serious TEAEs, or grade 3 or 4 TEAEs.
Discussion
This Phase 1 study was primarily aimed at exploring the combination of influenza antiviral drugs that have different modes of action, to circumvent the challenge of antiviral resistance that may develop with monotherapy. No clinically relevant drug-drug interactions were noted when pimodivir was administered with oseltamivir in healthy volunteers. After single-and multiple-dose administration of pimodivir in healthy volunteers, some accumulation was observed (1.2-and 1.8-fold increase in C max and AUC, respectively, between Day 1 and Day 10) and steady-state had been reached prior to Day 8. Overall, there were no important safety concerns reported with pimodivir alone or in combination with oseltamivir.
The co-administration of pimodivir and oseltamivir did not change the AUC 12h and C min of pimodivir in steady-state, but it increased the C max of pimodivir by 31% based on the geometric mean ratio. The increase in pimodivir C max is not considered to be clinically relevant due to its transient nature and the modest intrinsic variability in pimodivir pharmacokinetics. The mechanism for this interaction is unknown. Pimodivir and oseltamivir in combination had no effect on AUC 12h of oseltamivir and there was a slight change in the C min and C max . Furthermore, all primary pharmacokinetic parameters of oseltamivir carboxylate (active metabolite of oseltamivir) remained comparable when oseltamivir was given alone or in combination with pimodivir.
The combination of pimodivir and oseltamivir was not associated with any increase in the frequency or severity of TEAEs when compared with pimodivir or oseltamivir These data supported the Phase 2b study of pimodivir with or without oseltamivir in patients with acute uncomplicated seasonal influenza (TOPAZ; NCT02532283) [17] . In this Phase 2b, double-blind, placebo-controlled study, pimodivir 600 mg b.i.d. resulted in a significant decrease in nasal viral load AUC over 7 days compared to placebo; combination pimodivir 600 mg b.i.d. and oseltamivir 75 mg b.i.d. resulted in significantly lower AUC nasal viral load compared with pimodivir 600 mg alone. No safety concerns were noted with pimodivir treatment. Nausea and diarrhoea were the most commonly reported adverse events; the incidence of diarrhoea was more common with pimodivir 600 mg b.i.d. (as mono-or combination therapy) compared to 300 mg b.i.d. [17] .
In conclusion, the co-administration of pimodivir and oseltamivir in healthy volunteers had no clinically relevant drug-drug interactions, indicating that dose adjustment of pimodivir or oseltamivir is not necessary when the drugs are used in combination. No safety concerns were identified with pimodivir 600 mg b.i.d. alone or in combination with oseltamivir in healthy volunteers. These findings, together with the previous study data, provide valuable information for conducting future studies to evaluate the pimodivir and oseltamivir combination as a novel therapeutic option for influenza infection. 
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